Related Experiment Video

Updated: Jun 10, 2025

Visualization of Replisome Encounters with an Antigen Tagged Blocking Lesion
08:24

Visualization of Replisome Encounters with an Antigen Tagged Blocking Lesion

Published on: July 27, 2021

1.4K

Targeting therapeutic vulnerabilities in T-PLL

Marwan Kwok1,2, Tatjana Stankovic1

  • 1University of Birmingham.

Blood
|October 10, 2024
PubMed
Summary

No abstract available in PubMed .

More Related Videos

MISSION LentiPlex Pooled shRNA Library Screening in Mammalian Cells
09:12

MISSION LentiPlex Pooled shRNA Library Screening in Mammalian Cells

Published on: December 21, 2011

18.6K
Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.2K

Related Experiment Videos

Last Updated: Jun 10, 2025

Visualization of Replisome Encounters with an Antigen Tagged Blocking Lesion
08:24

Visualization of Replisome Encounters with an Antigen Tagged Blocking Lesion

Published on: July 27, 2021

1.4K
MISSION LentiPlex Pooled shRNA Library Screening in Mammalian Cells
09:12

MISSION LentiPlex Pooled shRNA Library Screening in Mammalian Cells

Published on: December 21, 2011

18.6K
Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.2K

Related Concept Videos

Translesion DNA Polymerases02:10

Translesion DNA Polymerases

9.9K
Translesion (TLS) polymerases rescue stalled DNA polymerases at sites of damaged bases by replacing the replicative polymerase and installing a nucleotide across the damaged site. Doing so, TLS allows additional time for the cell to repair the damage before resuming regular DNA replication.
TLS polymerases are found in all three domains of life - archaea, bacteria, and eukaryotes. Of the different classes of TLS polymerases, members of the Y family are fitted with specialized structures that...
9.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K

Articles linked to this work by shared authors, journal, and citation graph.

Mutant ribosomal protein RPS15 drives B cell malignancy through oxidative stress and genomic instability.

Nature communications·2026

Tracking Rare Single Donor and Recipient Immune and Leukemia Cells after Allogeneic Hematopoietic Cell Transplantation Using Mitochondrial DNA Mutations.

Blood cancer discovery·2024

DNA damage response defects in hematologic malignancies: mechanistic insights and therapeutic strategies.

Blood·2024

SF3B1 hotspot mutations confer sensitivity to PARP inhibition by eliciting a defective replication stress response.

Nature genetics·2023

Signatures of TOP1 transcription-associated mutagenesis in cancer and germline.

Nature·2022

Correction: Kwok et al. Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives. Cancers 2021, 13, 4681.

Cancers·2022

Recipient Endothelial IRF1 mediates IFNγ-driven tissue tolerance in mouse models of acute Graft-versus-Host Disease.

Blood·2026

A first-in-class RNA degrader reduces c-MYC expression and myeloma cell survival in preclinical models.

Blood·2026

Characteristics of Donor and Recipient Clonal Hematopoiesis in Nonmyeloablative Transplant for Sickle Cell Disease.

Blood·2026

1F10, a λ Light Chain Amyloid-Specific Monoclonal Antibody for Targeted Therapy of AL Amyloidosis.

Blood·2026

Clinical and Genomic Convergence of High-Risk CCUS and Lower-Risk Myelodysplastic Syndromes/Neoplasms.

Blood·2026

Prime editing enables drug-controllable T-cell therapies with clinical immunosuppression.

Blood·2026

Survivin mRNA lipid nanoparticles and CTLA-4 inhibitor co-delivery activates anti-tumor cytotoxic T-lymphocytes for oral cancer immunotherapy.

Medical oncology (Northwood, London, England)·2026

Species-specific functions of CSRP3 in satellite cell-driven muscle regeneration and relevance to porcine stem cell therapy.

Cell regeneration (London, England)·2026

Are SGLT2 inhibitors really associated with increased urinary tract infection risk? A trial-level meta-analysis across type 2 diabetes, heart failure, and chronic kidney disease.

Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences·2026

Mechanistic basis of G595R-mediated resistance to entrectinib in TRK kinase: a structural-energetic perspective.

Journal of molecular modeling·2026

Crossing the milestone: landmark-based conditional survival after first-line CDK4/6 inhibitor therapy in HR+/HER2-metastatic breast cancer.

Breast cancer (Tokyo, Japan)·2026

Beyond nuclear export: chromatin-bound XPO1/CRM1 as a transcriptional scaffold.

International journal of hematology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us